Trilomer-DLL3 conjugate

Trilomer-DLL3 conjugate is a peptide-drug conjugate (PDC) being developed by Trilo Therapeutics for the treatment of DLL3-expressing malignancies, such as small cell lung cancer (SCLC). The drug is built upon the proprietary Trilomer® platform, which utilizes mirror-image D-amino acid cyclic peptides. These D-peptides are engineered to be highly stable, protease-resistant, and non-immunogenic, providing a pharmacokinetic profile distinct from traditional L-peptide or antibody-based therapies. The conjugate functions as a bivalent or biparatopic binder to Delta-like ligand 3 (DLL3), an inhibitory Notch ligand that is frequently overexpressed on the surface of neuroendocrine tumors. Upon binding to the target, the Trilomer delivers a conjugated cytotoxic or radionuclide payload directly to the cancer cells to induce cell death, operating with a mechanism of action similar to an antibody-drug conjugate (ADC) but with the advantages of a smaller, synthetic scaffold.

Other names

Trilomer-DLL3Trilomer-DLL-3Trilomer-DLL 3DLL3-targeting Trilomer conjugateDLL-3-targeting Trilomer conjugateDLL 3-targeting Trilomer conjugate